Emerson's PlantWeb® architecture to digitally automate new plant for first monoclonal antibody drugs in China


PlantWeb automates Shanghai CP Guojian Pharmaceutical's new plant for the first monoclonal antibody drugs in China.

High resolution image


Grace Capwell
Emerson Automation Solutions
+1 (512) 834-7214

Integration by DeltaV system and FOUNDATION fieldbus to speed production of drugs for unmet medical needs

SINGAPORE (March 27, 2008) – Emerson Process Management has been chosen to design and install its advanced PlantWeb® digital plant architecture to digitally automate Shanghai CP Guojian Pharmaceutical Company's new API production suite  which will have the largest mammalian cell-culture system in Asia.  Located in the Zhangjiang Hi-Tech Park in Shanghai, the new plant is expected to begin producing the first monoclonal antibody drugs in China by August, 2008.

Emerson was selected by M+W Zander of Shanghai, the engineering procurement contractor, to design the plant's automation approach to take advantage of PlantWeb architecture with FOUNDATION™ fieldbus instrumentation for networking intelligent process instrumentation.  The PlantWeb approach will use its DeltaV digital automation system to also integrate variable frequency drives using DeviceNet, and all On/Off valves using Asi bus.  Integration with the DeltaV systems speeds installation and commissioning for fast start-up which is key for biopharmaceutical plants, and also includes DeltaV Batch software for process optimization and streamlined compliance.

To further speed startup, Emerson is supplying its AMS® Suite software that communicates with smart field devices for efficient commissioning.  Later, AMS Suite will enable predictive maintenance by monitoring diagnostics running in field instrumentation and alerting plant personnel to issues that need maintenance attention before they affect or shut down operations. The instrumentation includes Emerson's Rosemount® temperature transmitters, pressure transmitters, and flow meters as well as Fisher® control valves with FIELDVUE® digital valve controllers are also being deployed in key locations throughout the process.

Emerson's solution will reduce the complexity of field wiring and support asset management of the smart field devices. The fieldbus technology will be applied to all process control valves and many of the plant's 2000 analog input/output control signals. Emerson engineers will also configure and integrate all field devices with the control system and provide necessary on-site services to validate the system before start-up. 

"Emerson has demonstrated high capability in pharmaceutical applications, and their engineers are very experienced in adapting the fieldbus technology to batch production systems," said Mr. David Liu, project manager for M+W Zander. "Our customer has great confidence in their ability to deliver an advanced solution for this unique process."

The Emerson solution is intended to meet the end-user's goal of applying the most advanced technology to all phases of pharmaceutical production while keeping costs low, meeting the construction schedule, and achieving a smooth start-up.  Company officials expect to meet international standards with the products of this facility.

Additional resources:
• Join the Emerson Exchange 365 Community
• Connect with Emerson Automation Solutions via
   Twitter Facebook LinkedIn Google+ YouTube

About Emerson
Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. Our Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Emerson Commercial and Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency, and create sustainable infrastructure. For more information visit Emerson.com.

Please enable JavaScript to use this website.